How to Design an AI-Simulated Experiment

Begin with a real decision: which two onboarding messages should enter a live test, which response plan needs preparation, or which concept requires another interview round. An estimand turns that decision into a comparison. It specifies the population, treatment, comparator, outcome, and time window.

Avoid broad goals such as 'predict customer behavior.' A workable specification is: among first-time self-serve buyers represented by this evidence packet, how does a proof-led landing-page message change coded trust objections relative to the current page during an initial evaluation conversation? This is still a simulated contrast, but it is inspectable.

Write what the result may change and what it may not. If the simulation can drop a clearly confusing treatment but cannot set a revenue forecast, record that boundary before results appear.

A treatment bundle makes interpretation difficult. If the new variant changes headline, price framing, social proof, and call to action, a difference cannot be attributed to one element. Bundles can still be compared as product packages, but the claim must concern the package rather than a component.

Preserve fidelity. Summarizing the control in two sentences while giving the treatment a polished full brief biases exposure. Include the same channel constraints, timing, surrounding content, and interaction rules. Remove labels such as 'new' or 'improved' unless users would see them.

Archive exact treatment files with stable IDs. The report should point to A-01 and B-01 rather than relying on a later copy-and-paste reconstruction.

Useful sources include customer interviews, support themes, survey data, behavioral analytics, product research, market constraints, and policy requirements. Map each consequential agent attribute to evidence or label it as a modeling choice. Do not fill every gap with a confident demographic stereotype.

Deep interview-grounded research shows that richer context can improve behavioral representation on held-out measures, but it does not guarantee population validity. Keep a separate evaluation set where possible and avoid claiming that a small evidence packet represents an entire market.

Create an omission review. Ask which users experience the decision differently, who is absent from available data, and which stakeholder can block or amplify the outcome. Test plausible population variants when those gaps could reverse the shortlist.

Agent output is unstructured, so the measurement layer needs discipline. A primary outcome might be the presence of a specified trust objection, completion of an intended action, time to escalation, or selection among defined options. Sentiment alone is rarely sufficient because positive language may coexist with refusal.

Write examples and counterexamples for every code. Use human review, structured model coding, or both, and audit agreement on a sample. Keep coders blind to treatment where possible. Record missing and ambiguous outputs rather than forcing every run into a clean category.

Exploratory mechanisms can generate hypotheses, but they should not replace the primary outcome after the favored treatment underperforms. This preregistration-lite discipline reduces narrative cherry-picking.

The manifest should contain source IDs, treatment IDs, agent definitions, model and prompt versions, tool versions, sampling settings, timestamps, seeds where supported, exposure order, assignment logic, and coding rules. MIASE provides a useful minimum-information principle even though LLM-agent systems require additional generative details.

Repeat the control before interpreting treatment differences. Then pair or balance runs so configuration changes do not coincide with arm changes. Report distributions, not one representative transcript. Small run sets should use descriptive language rather than probability claims.

Add sensitivity variants for contested evidence, population mix, model version, treatment order, and influential assumptions. A recommendation that reverses under a minor plausible change should advance only as a hypothesis requiring stronger live evidence.

End each treatment in one of four states: advance, revise, drop, or unresolved. Give a reason tied to the prespecified outcome and risk register. A polished narrative is supporting material, not the decision rule. Preserve minority and tail failure modes that an average could hide.

State which real observation would invalidate the simulation. For an advancing treatment, define the live population, assignment unit, primary metric, guardrails, analysis window, and stopping rule. Do not use simulated effect magnitude as a production power assumption unless it has demonstrated local calibration.

Assign a human owner and review date. After real evidence arrives, compare it with the frozen simulation and update the calibration ledger. This closes the experiment loop instead of treating simulation as a one-time prediction artifact.